Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity reiterated a “hold” rating on shares of Dendreon in a research note to investors on Wednesday, May 23rd. Separately, analysts at Maxim Group initiated coverage on shares of Dendreon in a research note to investors on Friday, May 18th. They set a “sell” rating and a $5.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note to investors on Wednesday, May 9th. They now have a $9.25 price target on the stock.
Dendreon traded up 1.52% on Monday, hitting $5.9999. Dendreon has a 1-year low of $5.69 and a 1-year high of $42.00. The company’s market cap is $886.5 million.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.